September 20, 2019 / 6:47 AM / a month ago

BRIEF-Abivax H1 Operating Loss Widens To 17.2 Million Euros

Sept 20 (Reuters) - ABIVAX SA:

* REPORTED ON THURSDAY H1 OPERATING LOSS EUR 17.2 MILLION VERSUS LOSS OF EUR 8.6 MILLION YEAR AGO

* H1 REVENUES EUR 3.8 MILLION VERSUS EUR 1.8 MILLION YEAR AGO

* H1 LOSS FOR THE PERIOD EUR 14.2 MILLION VERSUS LOSS OF EUR 7.2 MILLION YEAR AGO

* ABX464: TOP-LINE DATA AFTER 2 MONTHS OF INDUCTION TREATMENT ARE EXPECTED AROUND THE END OF 2020

* ABX464-301: TOP-LINE DATA EXPECTED DURING SUMMER 2020

* ABX196: TOP-LINE RESULTS FROM DOSE-ESCALATION PART EXPECTED DURING SUMMER 2020

* ABX196 TO MOVE INTO PHASE 1/2 TRIAL IN HEPATOCELLULAR CARCINOMA

* AVAILABLE FUNDING SUSTAINS OPERATIONS UNTIL END OF Q2 2020

Source text for eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below